Systemic chemotherapy for the treatment of metastatic melanoma.

Cancer: Principles and Practice of Oncology.

1991 • 8,402 citations

Thalidomide is an inhibitor of angiogenesis.

1994 • 2,460 citations

Randomized Phase III Study of Temozolomide Versus Dacarbazine in the Treatment of Patients With Advanced Metastatic Malignant Melanoma

2000 • 1,252 citations

Discovery of betulinic acid as a selective inhibitor of human melanoma that functions by induction of apoptosis

1995 • 842 citations

A Southwest Oncology Group study

1993 • 778 citations

Phase III Multicenter Randomized Trial of the Dartmouth Regimen Versus Dacarbazine in Patients With Metastatic Melanoma

1999 • 756 citations

bcl-2 antisense therapy chemosensitizes human melanoma in SCID mice

1998 • 496 citations

Chemosensitisation of malignant melanoma by BCL2 antisense therapy

2000 • 487 citations

Durability of Complete Responses in Patients With Metastatic Cancer Treated With High-Dose Interleukin-2

1998 • 480 citations

Cell cycle and apoptosis: Common pathways to life and death

1995 • 404 citations

Antitumor activity and pharmacokinetics in mice of 8-carbamoyl-3-methyl-imidazo[5,1-d]-1,2,3,5-tetrazin-4(3H)-one (CCRG 81045; M & B 39831), a novel drug with potential as an alternative to dacarbazine.

1987 • 386 citations

Continuous low dose Thalidomide: a phase II study in advanced melanoma, renal cell, ovarian and breast cancer

2000 • 346 citations

Temozolomide, a Novel Alkylating Agent with Activity in the Central Nervous System, May Improve the Treatment of Advanced Metastatic Melanoma

2000 • 315 citations

Cancer Research Campaign phase II trial of temozolomide in metastatic melanoma.

1995 • 290 citations

Molecular controls of growth arrest and apoptosis: p53-dependent and independent pathways.

1995 • 282 citations

Combination chemotherapy with cisplatin, carmustine, dacarbazine, and tamoxifen in metastatic melanoma.

1984 • 234 citations

Reversal of acquired resistance to doxorubicin in P388 murine leukemia cells by tamoxifen and other triparanol analogues.

1984 • 182 citations

Randomized, double-blind, placebo-controlled trial comparing the response rates of carmustine, dacarbazine, and cisplatin with and without tamoxifen in patients with metastatic melanoma. National Cancer Institute of Canada Clinical Trials Group.

1996 • 176 citations

A phase II trial of taxol in metastatic melanoma

1990 • 175 citations

Cells en route to apoptosis are characterized by the upregulation of c‐fos, c‐myc, c‐jun, cdc2, and RB phosphorylation, resembling events of early cell‐cycle traverse

1995 • 144 citations

Antiapoptotic bcl-2 and bcl-xL in advanced malignant melanoma

2000 • 140 citations

Effective combination chemo/hormonal therapy for malignant melanoma: Experience with three consecutive trials

1992 • 139 citations

Expression of Bcl-2 family members in human melanocytes, in melanoma metastases and in melanoma cell lines

1998 • 134 citations

Apoptosis and signal transduction: clues to a molecular mechanism

1993 • 119 citations

Betulin and lupeol in bark from four white-barked birches

1988 • 118 citations

A promising interferon plus four-drug chemotherapy regimen for metastatic melanoma.

1992 • 114 citations

The importance of tamoxifen to a cisplatin-containing regimen in the treatment of metastatic melanoma

1989 • 114 citations

Effect of temozolomide on central nervous system relapse in patients with advanced melanoma

2002 • 106 citations

bcl-2 Protein Expression in Cutaneous Malignant Melanoma and Benign Melanocytic Nevi

1995 • 101 citations

A randomized phase III study comparing dacarbazine, BCNU, cisplatin and tamoxifen with dacarbazine and interferon in advanced melanoma

2000 • 101 citations

Human melanocytes and melanoma cells constitutively express the Bcl-2 proto-oncogene in situ and in cell culture.

1995 • 97 citations

Characteristics of prognosis and response to an imidazole carboxamide in malignant melanoma

1971 • 94 citations

Randomized phase II trial of BCDT [carmustine (BCNU), cisplatin, dacarbazine (DTIC) and tamoxifen] with or without interferon alpha (IFN-α) and interleukin (IL-2) in patients with metastatic melanoma

1998 • 88 citations

Phase II randomized study of dacarbazine, carmustine, cisplatin and tamoxifen versus dacarbazine alone in advanced melanoma patients

2001 • 84 citations

Dolastatin-10 in Metastatic Melanoma: A Phase II and Pharmokinetic Trial of the California Cancer Consortium

2001 • 83 citations

C-Myc Down-Regulation Increases Susceptibility to Cisplatin through Reactive Oxygen Species-Mediated Apoptosis in M14 Human Melanoma Cells

2001 • 79 citations

Immunohistochemical analysis of Bcl-2 protein regulation in cutaneous melanoma.

1995 • 79 citations

Tamoxifen modulation of cisplatin sensitivity in human malignant melanoma cells.

1993 • 77 citations

Role for Bcl-xLin the Regulation of Apoptosis by EGF and TGFβ1 in c-myc Overexpressing Mammary Epithelial Cells

1996 • 75 citations

Phase III Clinical Trial of the Combination of Cisplatin, Dacarbazine, and Carmustine With or Without Tamoxifen in Patients With Advanced Malignant Melanoma

1999 • 74 citations

O6-alkylguanine-DNA alkyltransferase depletion and regeneration in human peripheral lymphocytes following dacarbazine and fotemustine.

1991 • 73 citations

O6-methylguanine formation, repair protein depletion and clinical outcome with a 4 hr schedule of temozolomide in the treatment of advanced melanoma: Results of a phase II study

2000 • 69 citations

Immunohistochemical expression of BCL‐2 in melanomas and intradermal nevi

1994 • 69 citations

A phase III randomized trial of dacarbazine and carboplatin with and without tamoxifen in the treatment of patients with metastatic melanoma

1999 • 68 citations

Palliative therapy of melanoma patients with fotemustine. Inverse relationship between tumour load and treatment effectiveness. A multicentre phase II trial of the EORTC-Melanoma Cooperative Group (MCG)

1995 • 62 citations

Dacarbazine, cisplatin and carmustine, with or without tamoxifen, for metastatic melanoma: 5-year follow-up

1995 • 62 citations

Dacarbazine–vindesine versus dacarbazine–vindesine–cisplatin in disseminated malignant melanoma. A randomised phase III trial

1998 • 61 citations

Modulation of cisplatin resistance in human malignant melanoma cells.

1992 • 60 citations

Phase II study of carmustine, dacarbazine, cisplatin, and tamoxifen in advanced melanoma: a Southwest Oncology Group study.

1998 • 58 citations

Evaluation of efficacy of adjuvant rIFN-alfa-2a in melanoma patients with regional nodal metastases (abstract)

1995 • 57 citations

Effective chemotherapy for melanoma after treatment with interleukin-2

1992 • 57 citations

Cleavage of Bcl-2 in oxidant- and cisplatin-induced apoptosis of human melanoma cells

2001 • 57 citations

Increased repair of O⁶-alkylguanine DNA adducts in glioma-derived human cells resistant to the cytotoxic and cytogenetic effects of 1, 3-bis(2-chloroethyl)-1-nitrosourea

1986 • 55 citations

Phase III trial of melacine?? melanoma theraccine versus combination chemotherapy in the treatment of stage IV melanoma

1997 • 46 citations

Paclitaxel and tamoxifen

2000 • 45 citations

Mutated N-ras upregulates Bcl-2 in human melanoma in vitro and in SCID mice

1999 • 43 citations

Taxol in malignant melanoma.

1993 • 42 citations

Phase II evaluation of bryostatin-1 in metastatic melanoma

2001 • 41 citations

Reversal of acquired resistance to adriamycin in CHO cells by tamoxifen and 4-hydroxy tamoxifen: role of drug interaction with alpha 1 acid glycoprotein

1990 • 40 citations

Activity of the dolastatin analogue, LU103793, in malignant melanoma

2001 • 37 citations

Cisplatin and carboplatin combination as second-line chemotherapy in dacarbazine-resistant melanoma patients

2001 • 35 citations

Phase II trial of docetaxel (Taxotere) in patients with metastatic melanoma previously untreated with cytotoxic chemotherapy

1996 • 34 citations

Positive phase II study in the treatment of advanced malignant melanoma with fotemustine

1991 • 33 citations

Epidermal growth factor modifies cell cycle control in A431 human squamous carcinoma cells damaged by ionizing radiation.

1994 • 28 citations

Treatment of Stage IV Malignant Melanoma with Dacarbazine, Carmustine, Cisplatin, and Tamoxifen Regimens: A University of South Florida and H. Lee Moffitt Melanoma Center Study

1992 • 25 citations

Chemoimmunotherapy with bleomycin, vincristine, lomustine, dacarbazine (BOLD) plus interferon α for metastatic melanoma: a multicentre phase II study

1997 • 24 citations

Phase II trial of escalated dose of tirapazamine combined with cisplatin in advanced malignant melanoma

1999 • 23 citations

Interim Report of Phase II Study of New Nitrosourea S 10036 in Disseminated Malignant Melanoma

1988 • 23 citations

Prostaglandin synthesis in human cancer cells: Influence of fatty acids and butyrate

1995 • 21 citations

A Phase I and pharmacokinetic study of high dose tamoxifen and weekly cisplatin in patients with metastatic melanoma

1997 • 21 citations

Therapy for metastatic melanoma: effective combination of dacarbazine, carmustine, cisplatin and tamoxifen.

1993 • 20 citations

A phase II study of high dose tamoxifen and weekly cisplatin in patients with metastatic melanoma

2001 • 19 citations

A clinical trial of intravenous vinorelbine tartrate plus tamoxifen in the treatment of patients with advanced malignant melanoma

2000 • 17 citations

Approaches for drug development in treatment of advanced melanoma.

1988 • 16 citations

Combined treatment with dacarbazine, cisplatin, fotemustine and tamoxifen in metastatic malignant melanoma

1998 • 15 citations

Fotemustine — an advance in the treatment of metastatic malignant melanoma

1992 • 14 citations

Fotemustine plus dacarbazine in advanced stage III malignant melanoma

1992 • 11 citations

Hepatic vascular toxicity of dacarbazine (DTIC): Not a rare complication

1989 • 10 citations

Phase II Trial of CI-980 in Patients with Disseminated Malignant Melanoma and no Prior Chemotherapy – A Southwest Oncology Group Study

2001 • 8 citations

Phase II study of a closely spaced ifosfamide—cisplatin schedule with the addition of G-CSF in advanced non-small-cell lung cancer and malignant melanoma

1996 • 7 citations